Initial Results Positive For Valneva/Pfizer's Lyme Disease Vaccine In First Phase II Study
Role Of Infectious Disease Prevention Highlighted
Executive Summary
Speciality vaccine biotech Valneva outlines seroconversion rates and safety of candidate Lyme disease vaccine that it is co-developing with partner Pfizer.